Genetic variability in <it>CYP3A4 </it>and <it>CYP3A5 </it>in primary liver, gastric and colorectal cancer patients
<p>Abstract</p> <p>Background</p> <p>Drug-metabolizing enzymes play a role in chemical carcinogenesis through enzymatic activation of procarcinogens to biologically reactive metabolites. The role of gene polymorphisms of several cytochrome P450 enzymes in digestive canc...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2007-07-01
|
| Series: | BMC Cancer |
| Online Access: | http://www.biomedcentral.com/1471-2407/7/118 |
| _version_ | 1818758596613111808 |
|---|---|
| author | García Monserrat Martínez Carmen Sastre Javier Pizarro Rosa Ladero José M García-Martín Elena Gervasini Guillermo Diaz-Rubio Manuel Agúndez José AG |
| author_facet | García Monserrat Martínez Carmen Sastre Javier Pizarro Rosa Ladero José M García-Martín Elena Gervasini Guillermo Diaz-Rubio Manuel Agúndez José AG |
| author_sort | García Monserrat |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>Drug-metabolizing enzymes play a role in chemical carcinogenesis through enzymatic activation of procarcinogens to biologically reactive metabolites. The role of gene polymorphisms of several cytochrome P450 enzymes in digestive cancer risk has been extensively investigated. However, the drug-metabolizing enzymes with the broader substrate specificity, CYP3A4 and CYP3A5, have not been analyzed so far. This study aims to examine associations between common CYP3A4 and CYP3A5 polymorphisms and digestive cancer risk.</p> <p>Methods</p> <p>CYP3A4 and CYP3A5 genotypes were determined in 574 individuals including 178 patients with primary liver cancer, 82 patients with gastric cancer, 151 patients with colorectal cancer, and 163 healthy individuals.</p> <p>Results</p> <p>The variant allele frequencies for patients with liver cancer, gastric cancer, colorectal cancer and healthy controls, respectively, were: <it>CYP3A4*1B</it>, 4.8 % (95% C.I. 2.6–7.0), 3.7 % (0.8–6.6) 4.3% (2.0–6.6) and 4.3% (2.1–6.5); <it>CYP3A5*3</it>, 91.8 % (93.0–97.4), 95.7% (92.6–98.8), 91.7% (88.6–94.8) and 90.8% (87.7–93.9). The association between <it>CYP3A4*1B </it>and <it>CYP3A5*3 </it>variant alleles did not significantly differ among patients and controls. No differences in genotypes, allele frequencies, or association between variant alleles were observed with regard to gender, age at diagnosis, tumour site or stage.</p> <p>Conclusion</p> <p>Common polymorphisms on <it>CYP3A4 </it>and <it>CYP3A5 </it>genes do not modify the risk of developing digestive cancers in Western Europe.</p> |
| first_indexed | 2024-12-18T06:29:21Z |
| format | Article |
| id | doaj.art-17046c4ba1524ab18124bd38222da1df |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-12-18T06:29:21Z |
| publishDate | 2007-07-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-17046c4ba1524ab18124bd38222da1df2022-12-21T21:17:57ZengBMCBMC Cancer1471-24072007-07-017111810.1186/1471-2407-7-118Genetic variability in <it>CYP3A4 </it>and <it>CYP3A5 </it>in primary liver, gastric and colorectal cancer patientsGarcía MonserratMartínez CarmenSastre JavierPizarro RosaLadero José MGarcía-Martín ElenaGervasini GuillermoDiaz-Rubio ManuelAgúndez José AG<p>Abstract</p> <p>Background</p> <p>Drug-metabolizing enzymes play a role in chemical carcinogenesis through enzymatic activation of procarcinogens to biologically reactive metabolites. The role of gene polymorphisms of several cytochrome P450 enzymes in digestive cancer risk has been extensively investigated. However, the drug-metabolizing enzymes with the broader substrate specificity, CYP3A4 and CYP3A5, have not been analyzed so far. This study aims to examine associations between common CYP3A4 and CYP3A5 polymorphisms and digestive cancer risk.</p> <p>Methods</p> <p>CYP3A4 and CYP3A5 genotypes were determined in 574 individuals including 178 patients with primary liver cancer, 82 patients with gastric cancer, 151 patients with colorectal cancer, and 163 healthy individuals.</p> <p>Results</p> <p>The variant allele frequencies for patients with liver cancer, gastric cancer, colorectal cancer and healthy controls, respectively, were: <it>CYP3A4*1B</it>, 4.8 % (95% C.I. 2.6–7.0), 3.7 % (0.8–6.6) 4.3% (2.0–6.6) and 4.3% (2.1–6.5); <it>CYP3A5*3</it>, 91.8 % (93.0–97.4), 95.7% (92.6–98.8), 91.7% (88.6–94.8) and 90.8% (87.7–93.9). The association between <it>CYP3A4*1B </it>and <it>CYP3A5*3 </it>variant alleles did not significantly differ among patients and controls. No differences in genotypes, allele frequencies, or association between variant alleles were observed with regard to gender, age at diagnosis, tumour site or stage.</p> <p>Conclusion</p> <p>Common polymorphisms on <it>CYP3A4 </it>and <it>CYP3A5 </it>genes do not modify the risk of developing digestive cancers in Western Europe.</p>http://www.biomedcentral.com/1471-2407/7/118 |
| spellingShingle | García Monserrat Martínez Carmen Sastre Javier Pizarro Rosa Ladero José M García-Martín Elena Gervasini Guillermo Diaz-Rubio Manuel Agúndez José AG Genetic variability in <it>CYP3A4 </it>and <it>CYP3A5 </it>in primary liver, gastric and colorectal cancer patients BMC Cancer |
| title | Genetic variability in <it>CYP3A4 </it>and <it>CYP3A5 </it>in primary liver, gastric and colorectal cancer patients |
| title_full | Genetic variability in <it>CYP3A4 </it>and <it>CYP3A5 </it>in primary liver, gastric and colorectal cancer patients |
| title_fullStr | Genetic variability in <it>CYP3A4 </it>and <it>CYP3A5 </it>in primary liver, gastric and colorectal cancer patients |
| title_full_unstemmed | Genetic variability in <it>CYP3A4 </it>and <it>CYP3A5 </it>in primary liver, gastric and colorectal cancer patients |
| title_short | Genetic variability in <it>CYP3A4 </it>and <it>CYP3A5 </it>in primary liver, gastric and colorectal cancer patients |
| title_sort | genetic variability in it cyp3a4 it and it cyp3a5 it in primary liver gastric and colorectal cancer patients |
| url | http://www.biomedcentral.com/1471-2407/7/118 |
| work_keys_str_mv | AT garciamonserrat geneticvariabilityinitcyp3a4itanditcyp3a5itinprimarylivergastricandcolorectalcancerpatients AT martinezcarmen geneticvariabilityinitcyp3a4itanditcyp3a5itinprimarylivergastricandcolorectalcancerpatients AT sastrejavier geneticvariabilityinitcyp3a4itanditcyp3a5itinprimarylivergastricandcolorectalcancerpatients AT pizarrorosa geneticvariabilityinitcyp3a4itanditcyp3a5itinprimarylivergastricandcolorectalcancerpatients AT laderojosem geneticvariabilityinitcyp3a4itanditcyp3a5itinprimarylivergastricandcolorectalcancerpatients AT garciamartinelena geneticvariabilityinitcyp3a4itanditcyp3a5itinprimarylivergastricandcolorectalcancerpatients AT gervasiniguillermo geneticvariabilityinitcyp3a4itanditcyp3a5itinprimarylivergastricandcolorectalcancerpatients AT diazrubiomanuel geneticvariabilityinitcyp3a4itanditcyp3a5itinprimarylivergastricandcolorectalcancerpatients AT agundezjoseag geneticvariabilityinitcyp3a4itanditcyp3a5itinprimarylivergastricandcolorectalcancerpatients |